Physician profile
Benjamin H Cheek
NPI 1093712598
$3,535.92
in general payments reported to CMS, 2019-2025
31 companies · $515 in 2025
The $515 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $254 · 2021: $266 · 2022: $897 · 2023: $542 · 2024: $271 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978 · Consulting Fee: $250 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.41 |
| Consulting Fee | $250.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $644.96 | 2019-2025 | Myosure Tissue Removal Device, Fluent Fluid Management System, Novasure |
| Abbvie INC. | $545.20 | 2019-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $508.03 | 2019-2025 | Veozah |
| Fujirebio Diagnostics, Incorporated | $350.00 | 2022 | |
| Pfizer INC. | $213.66 | 2019-2024 | |
| Coopersurgical, INC. | $183.45 | 2020-2024 | Paragard T 380a, Summit Doppler |
| Boston Scientific Corporation | $175.28 | 2019-2022 | |
| Myriad Women'S Health, INC. | $127.28 | 2023 | Myrisk |
| Gen-Probe, INC. | $106.65 | 2019 | |
| Sumitomo Pharma America, INC. | $97.53 | 2023-2024 | Gemtesa, Myfembree |
| Caldera Medical, INC | $83.96 | 2022 | |
| Therapeuticsmd, INC. | $60.23 | 2019-2021 | |
| Myovant Sciences INC. | $48.24 | 2021-2022 | |
| Shield Therapeutics INC | $48.12 | 2023 | Accrufer |
| Mylan Pharmaceuticals INC. | $30.05 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $28.19 | 2021-2022 | |
| Becton, Dickinson and Company | $28.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.80 | 2022 | |
| Allergan, INC. | $25.15 | 2019 | |
| Biogen, INC. | $25.14 | 2025 | Zurzuvae |
| Organon LLC | $23.94 | 2024 | |
| Roche Diagnostics Corporation | $19.63 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.34 | 2025 | |
| Amgen INC. | $17.52 | 2019 | |
| Covidien LP | $16.24 | 2019 | |
| Daiichi Sankyo INC. | $15.16 | 2019 | |
| Duchesnay USA Incorporated | $15.15 | 2019 | |
| Exeltis, USA INC. | $14.33 | 2025 | Slynd |
| Avion Pharmaceuticals | $14.15 | 2021 | |
| Baxter Healthcare | $12.40 | 2022 | |
| Merck Sharp & Dohme LLC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Cheek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.